莫西沙星对社区获得性肺炎治疗作用的研究进展  

Development of moxifloxacin in treating community-acquired pneumonia

作　　者：朱文静[1] 崔卫华[1] 王少华[1] 张媛媛[1] 高纪军 

机构地区：[1]山东省青岛市市立医院 [2]山东省东营市利津县中心医院

出　　处：《中国临床药理学与治疗学》2015年第5期597-600,共4页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：社区获得性肺炎是指在医院外罹患的感染性肺实质炎症,是威胁人类健康的常见感染性疾病之一。莫西沙星作为第四代氟喹诺酮类药物,常用于社区获得性肺炎的治疗。其抗菌活性强,人体耐受性好,不良反应发生率低,具有广泛的临床应用前景。本文对莫西沙星的药动学、药效学和用药安全性问题进行综述,以为莫西沙星的合理应用提供参考。Community-acquired pneumonia（CAP）,the inflammation of lung parenchyma,is one of the common infectious disease threaten human health. Moxifloxacin is the fourth-generation fluoroquinolone,usually used to treat CAP. Moxifloxacin holds extensive promise for clinical application because of the high antibacterial activity,low incidences of adverse effect and well tolerated. This article summarizes pharmacokinetics, pharmacodynamics and safety of Moxifloxacin to provide reference for its reasonable application.

关 键 词：莫西沙星 社区获得性肺炎 药动学 药效学 安全性 

分 类 号：R969.1[医药卫生—药理学]